Resource impact template
NICE has produced a resource impact template that incorporates the following technology appraisal guidance for untreated extensive-stage small-cell lung cancer:
- Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (2026) NICE technology appraisal guidance 1167
- Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer (2025) NICE technology appraisal guidance 1041
- Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (2020) NICE technology appraisal guidance 638
This page was last updated: